PATH-11. PROGNOSTIC SIGNIFICANCE OF EPIGENETIC SUBTYPES AND CpGs ASSOCIATED WITH PROGRESSION TO G-CIMP LOW IN THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON
C. Mircea S. Tesileanu(Erasmus MC Cancer Institute), Pim J. French(Erasmus MC Cancer Institute), Thaís S. Sabedot(Universidade de Ribeirão Preto), Warren Mason(Princess Margaret Cancer Centre), Kenneth Aldape(National Cancer Institute), Martin J. van den Bent(Erasmus MC Cancer Institute), Anna K. Nowak(The University of Western Australia), Michael Weller(University Hospital of Zurich), S. C. Erridge(Western General Hospital), Iris de Heer(Erasmus MC Cancer Institute), Thierry Gorlia(European Organisation for Research and Treatment of Cancer), Pieter Wesseling(Radboud University Nijmegen), Helen Wheeler(The University of Sydney), Marc Sanson(Centre National de la Recherche Scientifique), Johan M. Kros(Erasmus MC), Houtan Noushmehr(Henry Ford Health System), Brigitta G. Baumert(Kantonsspital Graubünden), Wolfgang Wick(German Cancer Research Center), Alba A. Brandes(Istituto delle Scienze Neurologiche di Bologna), Jean Français Baurain(Cliniques Universitaires Saint-Luc), Vassilis Golfinopoulos(Champalimaud Foundation), Hendrikus J. Dubbink(Erasmus MC), Michael A. Vogelbaum(Moffitt Cancer Center), Paul M. Clément(Universitair Ziekenhuis Leuven)
Cited by 1
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data
|Nucleic Acids Research|2015|4.5k
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k